Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share

JERUSALEM, Nov. 30, 2015 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has […]

Categories: Press Releases|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, October 1, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place October 7-9, 2015 in Las Vegas. […]

Categories: Press Releases|Tags: |

Oramed Patent Allowed in the US for Oral Administration of Proteins

JERUSALEM, September 24, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been allowed by the United States Patent and […]

Categories: Press Releases|Tags: |

Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study

180 Patients Expected to be Enrolled in Study

JERUSALEM, September 9, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the Company’s Phase IIb […]

Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 4, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 17th Annual Global Investment Conference, taking place September […]

Categories: Press Releases|Tags: |

Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China

JERUSALEM, July 7, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has signed a non-binding Letter of Intent (LoI) for an investment and license agreement in China with […]

Categories: Press Releases|Tags: |

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

Company’s largest study to date with over 30 clinical sites in the United States to participate

JERUSALEM, June 30, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the first patient […]

Categories: Press Releases|Tags: |

Oramed Submits Protocol to U.S. FDA for its Phase IIb Oral Insulin Study

Company’s largest study to date with over 30 clinical sites in the U.S. to participate

JERUSALEM, June 30, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the […]

Categories: Press Releases|Tags: |

Oramed Granted Patent in Russia for Oral Administration of GLP-1

JERUSALEM, June 16, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Russian Federal Service for Intellectual Property has granted the Company a patent for its invention, titled “Methods and Compositions for Oral Administrations of […]

Categories: Press Releases|Tags: |

Oramed Announces Closing of $5.36 Million Registered Direct Offering

JERUSALEM, June 11, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a developer of oral drug delivery systems, today announced the closing of its previously-announced registered direct placement with institutional investors. Oramed has sold $5.36 million of shares of common stock at $7.50 per share. Investors […]

Categories: Press Releases|Tags: |